CCS Researchers of the Hartmann Lab Contribute to the Identification of a Loophole in Chronic Lympho
A team of medical researchers including the Hartmann CCS lab
have determined that a drug approved to treat chronic lymphocytic leukemia (CLL) may be less effective in a particular subset of patients. The study, which has been published in the latest issue of the Journal of Experimental Medicine, reveals that ibrutinib has a diminished capacity to delocalize and kill tumor cells expressing an adhesive protein called CD49d, but combining ibrutinib treatment with drugs that block CD49d activation could prevent the tumor cells from sheltering in lymphoid organs. Klick here for more details.